semaglutide removed from shortage list not for human use The FDA has semaglutide injection products (GLP-1) the FDA's Removal of Semaglutide and

Description

Glucagon-like peptide 1-receptor agonists and A1C: good for the heart but less so for the eyes

Medicaid coverage varies by state, as some state drug utilization data reflects coverage for GLP-1s for weight loss, but it is not universal

Key Difference: Tirzepatide (Mounjaro/Zepbound): Dual GIP/GLP-1 agonist Semaglutide (Wegovy/Ozempic): GLP-1 agonist only Effectiveness Difference: Tirzepatide: 15-22% average body weight loss Semaglutide: 10-15% average body weight loss Semaglutide is less potent but still highly effective and significantly more affordable than brand-name tirzepatide

Key Takeaway While Ozempic and other GLP-1s are being widely promoted, they are not safe or appropriate for individuals with eating disorders

Degraded medication can cause unexpected muscle pain , headaches , fatigue , or increased gastrointestinal issues that might be attributed to the medication itself rather than to degradation